SpringWorks Therapeutics EBIT

SpringWorks Therapeutics (SWTX) currently reports a EBIT of $-260M as of March 2025. That compares with $-360M in the prior-year period — up 26.4% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore SpringWorks Therapeutics's EBIT history and peer comparisons.

SpringWorks Therapeutics's EBIT increased from $-360M to $-260M — a 26.4% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SpringWorks Therapeutics's EBIT of $-260M is lower than the Healthcare sector average of $22B. That is roughly 101.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

SpringWorks Therapeutics reported $-260M in EBIT as of March 2025. That compares with $-360M in the prior-year period — up 26.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-260M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for SpringWorks Therapeutics, and consider following SWTX for alerts when major investors trade the stock.